Windtree Therapeutics, Inc. carries a market capitalization of 674,176.00, placing it among publicly traded companies globally. Its enterprise value stands at 13.49M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 674,176.00 |
| Enterprise Value | 13.49M |
Windtree Therapeutics, Inc. currently has 33.63M shares outstanding.
| Shares Outstanding | 33.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.04 |
| P/FCF Ratio | -0.05 |
| P/OCF Ratio | -0.05 |
Windtree Therapeutics, Inc. maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -111.35, indicating conservative leverage, while an interest coverage ratio of -33.09 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.33 |
| Quick Ratio | 0.27 |
| Debt / Equity | -111.35 |
| Debt / EBITDA | -0.80 |
| Interest Coverage | -33.09 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -172.27 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
| Income Tax | -3.51M |
| Effective Tax Rate | N/A |
Windtree Therapeutics, Inc.'s stock has declined approximately -97.46835% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | -97.46835% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.05 |
| Average Volume (20 Days) | N/A |
EBITDA reached -16.15M, while operating income came in at -16.25M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -16.25M |
| Pretax Income | -43.50M |
| Net Income | -39.99M |
| EBITDA | -16.15M |
| EBIT | -16.25M |
| Earnings Per Share (EPS) | -3.68 |
Windtree Therapeutics, Inc. holds 204,000.00 in cash and equivalents against 12.93M in total debt, resulting in a net debt position of 11.94M. Total book value stands at -889.34M, with working capital of -14.70M providing operational flexibility.
| Cash & Cash Equivalents | 204,000.00 |
| Total Debt | 12.93M |
| Net Debt | 11.94M |
| Equity (Book Value) | -889.34M |
| Book Value Per Share | -81.74 |
| Working Capital | -14.70M |
Windtree Therapeutics, Inc. produced -15.12M in operating cash flow over the past twelve months.
| Operating Cash Flow | -15.12M |
| Capital Expenditures | N/A |
| Free Cash Flow | -15.12M |
| FCF Per Share | -1.39 |
The company's payout ratio of 16.28 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.04 |
| Dividend Yield | N/A |
| Payout Ratio | 16.28 |
| Shareholder Yield | -2,494.25 |
| FCF Yield | -1,985.34 |
Windtree Therapeutics, Inc.'s most recent stock split took place on February 21, 2025 with a 50:1 split ratio.
| Last Split Date | 2/21/2025 |
| Split Ratio | 50:1 |
Windtree Therapeutics, Inc. posts an Altman Z-Score of -164.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -164.88 |